ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2114

Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?

Sepehr Mesdaghinia1, Julio Arturo Huapaya2, Brainerd Ewarien2 and Virginia D. Steen1, 1Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 2Medicine, MedStar Georgetown University Hospital, Washington, DC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Connective tissue diseases, histopathologic, interstitial lung disease, pulmonary fibrosis and serologic tests

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

–       Background/Purpose:
Interstitial lung disease (ILD) can be an early manifestation of an occult connective tissue disease (CTD).  It is important to separate these patients from Idiopathic pulmonary fibrosis (IPF), since the outcome and treatment are different. Recently, an international task force proposed criteria for patients with ILD and at least one feature from clinical, serologic or morphologic domains, calling it ‘Interstitial Pneumonia with Autoimmune Features (IPAF)’ (Fischer, 2015). We carefully reviewed ILD patients seen since 2008 to see if they had features suggestive of CTDs and also a possible flavor to help define subsets.

–       Methods:
We identified 374 patients with ILD who were seen at rheumatology and pulmonary clinics. Patients with clear IPF or a definable CTD were excluded (n=276) and the remaining 98 patients were thoroughly reviewed for the demographic, clinical, laboratory, and radiographic features. Those featured were entered in Excel database and analyzed from different aspects.

–       Results:
Of these 98 patients with ILD, 66 met criteria for IPAF, 14 patients met criteria for a CTD, 3 patients had IPF and 15 patients did not meet criteria for IPAF primarily due to lack of rheumatologic evaluation or complete serologic testing. Among 15 patients without IPAF, 4 patients had elevated CPK and aldolase that could not be used towards IPAF criteria. In comparison with IPF, our IPAF patients were younger (mean age 60.7). There were more women and African Americans (74% and 46% respectively) and smoking history did not seem to be a major contributing factor (only 32%), (Table 1). Table 2 describes the features (domains) that led to the diagnosis of IPAF. Among these IPAF patients, 77% had features suggestive of a specific CTD with scleroderma the most frequent at 41% (Table 3). Some patients did not have enough features to suggest a possible CTD (23%).
 

–       Conclusion:
IPAF is an important subgroup of patients who need to be better characterized. These patients are more commonly female and have serologic abnormalities. Further consideration may be helpful to include some other features in the criteria (e.g. elevated muscle enzymes). A large portion of patients with IPAF (77%) appeared to fit into a CTD subgroup which could be helpful in determining the best treatment. 

 

 

 


Disclosure: S. Mesdaghinia, None; J. A. Huapaya, None; B. Ewarien, None; V. D. Steen, None.

To cite this abstract in AMA style:

Mesdaghinia S, Huapaya JA, Ewarien B, Steen VD. Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/interstitial-pneumonia-with-autoimmune-features-ipaf-are-there-definable-subsets/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-pneumonia-with-autoimmune-features-ipaf-are-there-definable-subsets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology